Interpretation and insights into Surviving Sepsis Campaign:international guidelines for management of sepsis and septic shock 2026:transitioning from standardized management to precision-tailored therapy
Abstract
The Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026(SSC 2026)represent a full systematic revision based on the 2021 iteration,encompassing 129 consensus statements in total,46 of which are newly added recommendations. While retaining the well-established core tenets of sepsis care,including early identification,timely and appropriate anti-infective administration,infection source control and organ function support,the updated guidelines have introduced targeted revisions across key domains:sepsis screening strategies,antimicrobial stewardship,fluid resuscitation regimens,vasoactive agent dosing,adjunctive interventions and post-sepsis long-term management. Rather than focusing solely on the adjustments to individual recommendations,the most notable paradigm shift embedded in this update lies in its refined clinical decision-making logic. Building on the existing standardized diagnosis and treatment framework,the guidelines explicitly place greater weight on integrating infection pre-test probability,baseline disease severity,real-time dynamic physiological trajectories and individual patient phenotypes into every stage of therapeutic decision-making. Over recent years,landmark large-scale randomized controlled trials including CLASSIC,CLOVERS,BLING Ⅲand ANDROMEDA-SHOCK-2 have continuously fueled the evolution of sepsis management,driving clinical practice away from one-size-fits-all protocols and uniform hemodynamic targets toward risk stratification,iterative dynamic assessment and phenotype-specific individualized interventions. This review contextualizes the core updates of SSC 2026 alongside latest high-level clinical evidence,focusing on four priority domains:early recognition and anti-infective optimization,hemodynamic resuscitation strategies,evidence-based adjunctive therapies and post-sepsis long-term care. Aligned with real-world clinical practice in China,the authors further elaborate on the realistic implementation foundation,clinical applicability boundaries and future research priorities for the ongoing transition of sepsis care from standardized population-based management to precision-guided therapy.
Related
- 8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)
- Perioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.
- Pancreatic Intraductal Papillary Mucinous Neoplasm in a Carrier of a Reported Pathogenic BRCA2 Variant: Diagnostic Considerations and Management Using European and International Guidelines.
- Interpretation of the ERAS Society's "Guidelines for antenatal and postoperative care in cesarean delivery:2025 update"
- Reporting and interpretation of respiratory metagenomic results in clinical practice: a systematic review and consensus guidelines from the UK NHS Respiratory Metagenomics Network
BibTeX
@article{lei2026interpretation,
title = {{Interpretation and insights into Surviving Sepsis Campaign:international guidelines for management of sepsis and septic shock 2026:transitioning from standardized management to precision-tailored therapy}},
author = {WANG Lei and GE Xin and ZHAO Mingyan},
journal = {Zhongguo linchuang yanjiu},
year = {2026},
month = oct,
doi = {10.13429/j.cnki.cjcr.2026.10.001},
url = {https://doi.org/10.13429/j.cnki.cjcr.2026.10.001},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Interpretation and insights into Surviving Sepsis Campaign:international guidelines for management of sepsis and septic shock 2026:transitioning from standardized management to precision-tailored therapy
AU - WANG Lei
AU - GE Xin
AU - ZHAO Mingyan
PY - 2026
DA - 2026/10/26
JO - Zhongguo linchuang yanjiu
DO - 10.13429/j.cnki.cjcr.2026.10.001
UR - https://doi.org/10.13429/j.cnki.cjcr.2026.10.001
AB - The Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026(SSC 2026)represent a full systematic revision based on the 2021 iteration,encompassing 129 consensus statements in total,46 of which are newly added recommendations. While retaining the well-established core tenets of sepsis care,including early identification,timely and appropriate anti-infective administration,infection source control and organ function support,the updated guidelines have introduced targeted revisions across key domains:sepsis screening strategies,antimicrobial stewardship,fluid resuscitation regimens,vasoactive agent dosing,adjunctive interventions and post-sepsis long-term management. Rather than focusing solely on the adjustments to individual recommendations,the most notable paradigm shift embedded in this update lies in its refined clinical decision-making logic. Building on the existing standardized diagnosis and treatment framework,the guidelines explicitly place greater weight on integrating infection pre-test probability,baseline disease severity,real-time dynamic physiological trajectories and individual patient phenotypes into every stage of therapeutic decision-making. Over recent years,landmark large-scale randomized controlled trials including CLASSIC,CLOVERS,BLING Ⅲand ANDROMEDA-SHOCK-2 have continuously fueled the evolution of sepsis management,driving clinical practice away from one-size-fits-all protocols and uniform hemodynamic targets toward risk stratification,iterative dynamic assessment and phenotype-specific individualized interventions. This review contextualizes the core updates of SSC 2026 alongside latest high-level clinical evidence,focusing on four priority domains:early recognition and anti-infective optimization,hemodynamic resuscitation strategies,evidence-based adjunctive therapies and post-sepsis long-term care. Aligned with real-world clinical practice in China,the authors further elaborate on the realistic implementation foundation,clinical applicability boundaries and future research priorities for the ongoing transition of sepsis care from standardized population-based management to precision-guided therapy.
SN - 1674-8182
ER -